Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Nektar Therapeutics (NKTR) Tops Q3 EPS by 17c
November 6, 2019 4:40 PM ESTNektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.56), $0.17 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $29.2 million versus the consensus estimate of $26.4 million.
"We continue to make steady progress with our diverse portfolio of immuno-oncology and immunology programs," said Howard... More
